Cambridge, MA (March 4, 2013) Today, the Damon Runyon Cancer Research Foundation held its annual Accelerating Cancer Cures Research Symposium designed to foster communication and collaboration between cancer researchers in industry and academia to speed progress against cancer. Hosted by Millennium: The Takeda Oncology Company, the meeting included physician-scientists from Eli Lilly and Company, ARIAD, Celgene, Genentech, Merck, and Pfizer, as well as academic researchers from the top universities and research institutions in the nation.
Accelerating Cancer Cures is a unique collaboration between Damon Runyon, a prestigious cancer charity that supports the most innovative young cancer researchers, and leading biopharmaceutical companies. The goal of this multi-million dollar initiative is to rebuild the ranks of specially trained physician-scientists who conduct both the cutting-edge laboratory research to identify new therapeutics, as well as the clinical trials to bring these new treatments to patients. The companies involved in this initiative, while competitors in the marketplace, are committed to supporting the best young clinical investigators so that they can drive the next breakthroughs in cancer prevention, diagnosis and treatment.
The President and CEO of Millennium, Dr. Deborah Dunsire, opened the meeting with remarks that focused on the need for greater collaboration between industry and academia. Additionally, David Nathan, MD, President Emeritus, Dana-Farber Cancer Institute, and the Robert A. Stranahan Distinguished Professor of Pediatrics and Professor of Medicine, Harvard Medical School, delivered a keynote address about the promise of cancer research and the critical role of patient-oriented physician-scientists in advancing progress against the many forms of cancer. Richard B. Gaynor, MD, Vice President, Cancer Research/Clinical Investigation, of Lilly, and Alan Leventhal, Chairman and CEO of Beacon Capital Partner
|Contact: Yung S. Lie|
Damon Runyon Cancer Research Foundation